GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley Sells 35,506 Shares of Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 35,506 shares of the firm’s stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $93.82, for a total value of $3,331,172.92. Following the completion of the sale, the chief financial officer now owns 2,472 shares of the company’s stock, valued at approximately $231,923.04. This represents a 93.49 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Kevin Feeley also recently made the following trade(s):

• On Thursday, January 2nd, Kevin Feeley sold 1,430 shares of GeneDx stock. The shares were sold at an average price of $76.04, for a total transaction of $108,737.20.
• On Monday, December 16th, Kevin Feeley sold 3,728 shares of GeneDx stock. The stock was sold at an average price of $76.75, for a total transaction of $286,124.00.
• On Monday, December 9th, Kevin Feeley sold 1,137 shares of GeneDx stock. The stock was sold at an average price of $76.37, for a total transaction of $86,832.69.
• On Monday, December 2nd, Kevin Feeley sold 263 shares of GeneDx stock. The shares were sold at an average price of $78.39, for a total value of $20,616.57.
• On Thursday, November 21st, Kevin Feeley sold 12,019 shares of GeneDx stock. The stock was sold at an average price of $73.76, for a total value of $886,521.44.
• On Tuesday, October 29th, Kevin Feeley sold 274 shares of GeneDx stock. The shares were sold at an average price of $66.60, for a total value of $18,248.40.

GeneDx Price Performance

Shares of WGS opened at $89.38 on Friday. The stock has a market capitalization of $2.46 billion, a PE ratio of -28.74 and a beta of 2.02. The company has a 50 day moving average price of $78.01 and a 200-day moving average price of $53.19. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.27 and a current ratio of 2.40. GeneDx Holdings Corp. has a fifty-two week low of $2.85 and a fifty-two week high of $98.87.

GeneDx (NASDAQ:WGS) last announced its quarterly earnings results on Tuesday, October 29th. The company reported $0.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.25. GeneDx had a negative return on equity of 13.35% and a negative net margin of 31.25%. The business had revenue of $76.90 million for the quarter, compared to the consensus estimate of $64.98 million. During the same period last year, the business posted ($0.82) EPS. The business’s revenue was up 44.3% compared to the same quarter last year. Equities analysts predict that GeneDx Holdings Corp. will post -0.24 earnings per share for the current fiscal year.

Institutional Trading of GeneDx

Institutional investors have recently modified their holdings of the company. Driehaus Capital Management LLC acquired a new stake in GeneDx in the second quarter valued at approximately $11,335,000. Fred Alger Management LLC purchased a new stake in shares of GeneDx during the 3rd quarter valued at $16,731,000. Divisadero Street Capital Management LP acquired a new stake in shares of GeneDx in the 2nd quarter worth $5,886,000. Millennium Management LLC grew its stake in GeneDx by 193.5% during the 2nd quarter. Millennium Management LLC now owns 311,401 shares of the company’s stock worth $8,140,000 after buying an additional 205,318 shares during the last quarter. Finally, Raymond James & Associates acquired a new position in GeneDx during the 3rd quarter valued at about $8,090,000. 61.72% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

WGS has been the subject of a number of recent analyst reports. TD Cowen boosted their target price on shares of GeneDx from $75.00 to $118.00 and gave the company a “buy” rating in a research note on Tuesday. Wells Fargo & Company boosted their price objective on shares of GeneDx from $34.00 to $75.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 30th. Craig Hallum raised their target price on shares of GeneDx from $70.00 to $95.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. Finally, The Goldman Sachs Group boosted their price target on GeneDx from $54.00 to $70.00 and gave the company a “neutral” rating in a report on Wednesday, October 30th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $70.67.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.